Bentley, Sarah http://orcid.org/0000-0001-9914-8934
Findley, Amy
Chiva-Razavi, Sima
Naujoks, Christel
Patalano, Francesco
Johnson, Chloe
Arbuckle, Rob
Wolffsohn, James S.
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 20 May 2021
Accepted: 15 September 2021
First Online: 23 October 2021
Declarations
:
: Ethical approval was obtained from an Institutional Review Board (IRB), Copernicus Group Independent Review Board (CGIRB; IRB ref: ADE1-18-049), prior to any study related activities in the US, and from Salus IRB (IRB ref: Novartis CUNR844A2001) prior to any study related activities in Germany. In line with ethical requirements for research in France at the time of the research, a letter was submitted to the Conseil National de l'Ordre des Médecins (CNOM) to notify them of the study procedures and payments to recruiting health professionals. Written and verbal informed consent was obtained from every participant before each interview was conducted and before any other study activities.
: Not applicable.
: JW is a developer of the original NAVQ and has been engaged with Novartis on other projects and has received honoraria for speaker events, ad boards and other related activities. RA, SB, and AF are employed by Adelphi Values Patient-Centered Outcomes team, which received funding from Novartis Pharma AG to conduct the research described in this manuscript. The Adelphi Values team also work with many other pharmaceutical companies to perform Patient-Centered Outcomes research. CJ was employed by Adelphi Values Patient-Centered Outcomes at the time of the study. SC-R, FP,CN and GS are employed by Novartis Pharma AG. FP and CN own shares in Novartis.